JPRN-UMIN000018769已完成未知
Investigation of rituximab for candidate of high-risk living-donor renal transplantation - Investigation of rituximab for candidate of high-risk living-donor renal transplantation
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 76
研究概览
简要总结
There were 59 patients in the rituximab group and 17 in the non-rituximab group. The estimated glomerular filtration rate did not differ significantly between groups until 24 months after transplantation. Cytomegalovirus clinical symptoms , including fever over 38 degree and gastrointestinal symptoms , and the 5-year survival rates of death-censored graft loss did not differ significantly between groups.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) excluding 1)-4), 6) (see above) 2) impertinent recipient for this study assessed by main/co-scholar 3) without concensus of recipient
研究者
相似试验
终止
2 期
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia AHemophilia ANCT00306670Georgetown University2
已完成
不适用
Phase II study of rituximab in patients with severe systemic lupus erythematosusSystemic lupus erythematosusJPRN-UMIN000000763Zenyaku Kogyo Co., Ltd.30
已完成
2 期
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00074438Genentech, Inc.465
进行中（未招募）
1 期
An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky fillicular lymphoma - Watch and WaitAdvanced stage, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a)EUCTR2004-001621-16-CZniversity College London (UCL)600
已完成
不适用
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20Multiple myeloma expressing CD20JPRN-UMIN000000531Zenyaku Kogyo Co., Ltd.39